Reported complications described in some GLP-1 drug claims have included: Severe or persistent gastrointestinal symptoms , such as ongoing nausea, vomiting, or abdominal pain Delayed stomach emptying (gastroparesis) , which has been described by some individuals as involving bloating, nausea, vomiting, or difficulty tolerating food Intestinal complications , including reduced bowel activity (ileus), which may involve abdominal discomfort, cramping, or vomiting Gallbladder-related conditions , such as gallstones or gallbladder inflammation Blood-clot-related conditions , including deep vein thrombosis or pulmonary embolism, described in some reports and legal filings Vision-related problems , including reports involving non-arteritic anterior ischemic optic neuropathy (NAION) discussed in connection with semaglutide in certain contexts Not everyone who takes a GLP-1 medication experiences these issues, and the relationship between GLP-1 drugs and reported complications continues to be evaluated in legal proceedings

Pharmaceuticals (Basel, Switzerland), 18(3), 399.
You have the scheduling delay (often 2 to 4 weeks for a new patient appointment), the travel time, the waiting room, the appointment itself, the trip to the pharmacy, and any follow-up visits
Continue until effluent is clear (just as you would for a colonoscopy prep)
Subtypes include MEN 2A and MEN 2B, both associated with mutations in the RET proto-oncogene
Both companies are also investing in oral formulations, long-acting depot injections, and other delivery mechanisms that could transform how these peptides are administered